

Hiroshi Tomiyama, Ph.D.

Work Experience

2014 - current: President & CEO

2000: Joined Kotobuki Pharma

1997-1999: Postdoctoral Researcher

Division of Medicinal and Natural Products Chemistry (MNPC), College of Pharmacy,

The University of Iowa, USA

Research subject; The synthesis of catabolically stable C-glycoside analogue of cancer carbohydrate antigen toward cancer vaccine development.

Awards

*Medicinal Chemistry (Med. Chem.);*

2015: Breakthrough Award, Division of Medicinal Chemistry,

Pharmaceutical Society of Japan

Title: Discovery of ipragliflozin (Suglat®): A potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus

*Pharmaceutical Engineering (Pharm. Eng.);*

2022: The 21st Century research grants, Nagano Pharmaceutical Association

Title: The development of easy to split with fingers and easy to swallow of “KAWARA”

Orally Disintegrating tablets ®